Clinical Trials Logo

Donor Specific Antibodies clinical trials

View clinical trials related to Donor Specific Antibodies.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04665310 Withdrawn - Clinical trials for Acute Rejection of Renal Transplant

Evaluation of Anti-rejection Drug, Tacrolimus, in African-Americans With Kidney Transplant

Start date: September 1, 2018
Phase: Phase 4
Study type: Interventional

In spite of conventional immunosuppression with lymphocyte-depleting induction followed by tacrolimus- and mycophenolate-based regimens, African American (AA) renal transplant recipients experience higher rates of acute rejection (AR), donor specific antibodies (DSA), and graft failure. Envarsus Extended-Release (XR)® (ENV) is a novel extended-release formulation of tacrolimus with a favorable pharmacokinetic profile, even in the setting of CYP3A5*1 allele (rapid metabolizers). The investigator will evaluate the safety and efficacy of early dose escalation with ENV in AA recipients. The study hypothesis is that higher tacrolimus target concentrations may be achieved without typical dose-limiting toxicities, and this may ultimately result in lower incidence of early AR, DSA, and graft loss.